# Chai Discovery

## Company Overview
| Attribute | Details |
|-----------|---------|
| **Company Name** | Chai Discovery |
| **Founded** | 2024 |
| **Headquarters** | San Francisco, CA, USA |
| **Founders** | Joshua Meier, William Dent, Matthew McPartlon, Jacques Boitreaud |
| **Category** | AI Drug Discovery / Biotech |
| **One-Sentence Description** | OpenAI-backed AI biotech at $1.3B valuation with Eli Lilly partnership, predicting biochemical molecular structures for drug discovery |

## Funding
| Attribute | Details |
|-----------|---------|
| **Total Funding** | ~$230M |
| **Latest Round** | Series B - $130M (December 2025) |
| **Valuation** | $1.3B |
| **Key Investors** | Oak HC/FT (co-lead), General Catalyst (co-lead), OpenAI, Thrive Capital, Menlo Ventures, Dimension |

## Founders Background

### Joshua Meier
- Co-founder
- Former Facebook AI: Helped develop ESM1 (first transformer protein-language model)
- Spent 3 years at Absci (AI biotech)

### Other Founders
- William Dent
- Matthew McPartlon
- Jacques Boitreaud

Company was founded while working out of OpenAI's offices in San Francisco's Mission neighborhood.

## Key Partnerships

### Eli Lilly (January 2026)
- Major pharmaceutical partnership
- Lilly will use Chai's software for new medicine development
- Followed evaluation of Chai's model designs

## Products & Technology

### Chai-2
- Zero-shot antibody design platform
- Double-digit experimental hit rates
- Drug-like molecule properties
- Discovery in weeks vs months previously

### Core Capabilities
- AI models predicting biochemical molecular structures
- Biologics design for pharmaceutical companies
- Molecule reprogramming for cures

## OpenAI Connection
- OpenAI was one of Chai's first seed investors
- Founded in OpenAI's offices
- Strong AI research pedigree

## Competitive Position
Competing with:
- Absci
- Recursion Pharmaceuticals
- Insilico Medicine
- Isomorphic Labs (Google)
- Genesis Therapeutics

### Differentiation
- OpenAI backing and office connection
- Zero-shot antibody design
- Eli Lilly validation
- Speed advantage (weeks vs months)

## Strategic Notes
- OpenAI-backed = strong AI credibility
- $1.3B unicorn in ~1 year
- Eli Lilly partnership = pharma validation
- Zero-shot = no prior data needed
- Weeks vs months = 10x speed improvement
- Founded in OpenAI offices = unique origin
- ESM1 experience = protein modeling expertise
- Oak HC/FT + General Catalyst = top healthcare VCs

## Status
Active - Leading AI drug discovery unicorn

## Sources
- TechCrunch, BusinessWire, BioSpace, Yahoo Finance, Endpoints News
